Elevar Therapeutics Announces the Formation and Members of Scientific Advisory Board
Scientific Advisory Board formed with internationally recognized liver and biliary tract cancer physicians to support the advancement of solid tumor pipeline programs
Elevar plans for major 2025 oncology regulatory milestones- March 2025 PDUFA date and launch preparation for unresectable hepatocellular carcinoma- NDA Submission for lirafugratinib in second half 2025 for FGFR2 driven cholangiocarcinoma
FORT LEE, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a portfolio company of HLB Co., Ltd., today announced the formation of its Scientific Advisory Board (SAB) with internationally renowned experts in the discovery and development of next generation hepatocellular carcinoma and cholangiocarcinoma cancer therapies.
'We proudly welcome our newly formed Scientific Advisory Board, a distinguished group of oncology clinicians who will play a crucial role in supporting our research and development strategy. Their individual and collective expertise will be invaluable as we strive to make a meaningful impact in the fight against cancer,' commented Chris Galloway, M.D., senior vice president of clinical development and medical affairs at Elevar.
Mitesh Borad, M.D.
Mitesh J. Borad, M.D., is the Getz Family Research Professor and leads the Novel Therapeutics and Modalities Program at Mayo Clinic. Dr. Borad is an internationally recognized expert for treating patients with cholangiocarcinoma and has been extensively involved in developing novel cancer therapeutic platforms that leverage genomic medicine and gene/virus therapies, with a focus on tumors of the liver, bile ducts and pancreas. He has led the clinical development of novel anti-cancer agents in more than 50 first-in-human studies, including a multi-institutional team with collaborators at Mayo Clinic and the Translational Genomics Research Institute, which led to the discovery of fibroblast growth factor 2 (FGFR2) fusions in patients with intrahepatic cholangiocarcinoma, with the first demonstration of anti-tumor activity with FGFR inhibitors in this patient population. Subsequent work led to the FDA approval of three FGFR inhibitor cancer therapies.
Richard Kim, M.D.
Dr. Richard Kim is a Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center and a Professor of Oncology at the University of South Florida College of Medicine. Before joining Moffitt in 2010, Dr. Kim was an associate physician in gastrointestinal malignancies at the Cleveland Clinic Taussig Cancer Center and a clinical assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, OH. Dr. Kim's clinical and research interests focus on gastrointestinal tumors, in particular hepatobiliary and colon cancer. He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I, II and III trials using immunotherapy and novel targeted agents.
Daneng Li, M.D.
Daneng Li, M.D. is an Associate Professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li's clinical and academic research is focused on the multidisciplinary approach to treatment of patients with neuroendocrine tumors (NETs). He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics.
Rachna T Shroff, M.D., M.S.
Rachna T. Shroff, MD, MS, FASCO, serves as associate director of Clinical Investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC) and is a professor in the Department of Medicine, chief of the Division of Hematology and Oncology, medical director for the Oncology Service Line and associate dean for Clinical and Translational Research for the University of Arizona College of Medicine – Tucson. Dr. Shroff joined UACC from MD Anderson Cancer Center in Houston. She is a clinical and translational investigator focused on developing novel therapies for pancreatic and hepatobiliary cancers and has led numerous clinical trials focusing on pancreaticobiliary tumors. She was the national principal investigator for SWOG 1815, which investigated a triplet chemotherapy regimen as a potential new standard of care for biliary cancers.
About Elevar Therapeutics
Elevar Therapeutics, Inc., a fully owned subsidiary of HLB Group, is a fully integrated biopharmaceutical company built on the promise of elevating treatment outcomes for patients who have limited or inadequate therapeutic options. With expertise rooted in oncology, Elevar is focused on identifying and developing promising medicines for complex yet under-treated health conditions. Elevar's lead proprietary drug candidate is rivoceranib. The NDA for rivoceranib in combination with camrelizumab as a therapy for advanced or metastatic hepatocellular carcinoma (HCC) is currently under review by the FDA with a PDUFA action date scheduled for March 20, 2025. On December 2, 2023, Elevar acquired worldwide rights to develop and commercialize lirafugratinib (RLY-4008), an FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma (CCA) and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors. An NDA submission for lirafugratinib is planned for 2025.
Additional information is available at www.Elevar Therapeutics.com.
About HLB Group
The HLB Group is comprised of HLB Inc. (KOSDAQ:028300) and its affiliates with a diverse portfolio across biopharma, lifestyle, marine business, semiconductor and energy, united by the mission of improving all aspects of human life. Members of the HLB Group include HLB Innovation (KOSDAQ: 024850), HLB BioStep (KOSDAQ:278650), HLB Pharmaceutical (KOSDAQ:047920), HLB Life Science (KOSDAQ:067630), HLB Therapeutics (KOSDAQ:115450), HLB Panagene (KOSDAQ:046210) and HLB Global (KOSDAQ:003580). HLB Group's overseas affiliates include Elevar Therapeutics, Immunomic Therapeutics, a nucleic acid immunotherapy platform company, and Verismo Therapeutics, a CAR T platform oncology company, and a fully owned subsidiary of HLB Innovation, both based in the United States.
Contacts
Media: Jeanette BressiHead, Corporate Communications jbressi@elevartherapeutics.com 609-439-3997
Investors: Wade SmithChief Financial & Business Officer wsmith@elevartherapeutics.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
B.C. mom picks up her son's ADHD medication, is given an opioid instead
A mother on Vancouver Island is warning people to double check their prescriptions after she was accidentally dispensed the powerful opioid hydromorphone instead of her son's regular ADHD medication. Comox, B.C., resident Sarah Paquin, 31, says she still shudders to think about what could have happened to her nine-year-old son had her husband not noticed the medication looked different before he gave it to him. "It was terrifying," Paquin said, standing in her front yard and playing with one of her three boys. "One simple little mistake like that could have ended horribly." WATCH | 9-year-old dispensed opioid in pharmacy mix-up: Paquin says she didn't think too much of it when she went to pick up her son Declan's medication last week and the staff member at her local Shoppers Drug Mart pharmacy didn't check her ID or take out the prescription from the bag. The next day, her husband was about to give Declan his medication when he saw the pills were a different colour and shape than normal. Her husband looked at the bottle and noticed the prescription was for someone else, and that it was for hydromorphone. Right away he returned the pills to the pharmacy. "Immediately your mind goes to the worst case scenario," Paquin said. "The results could have been catastrophic and it just makes my heart sink to think about what could have happened." Hydromorphone is a powerful opioid that is two to eight times stronger than morphine and is often used to treat acute pain or chronic cancer pain. According to the Mayo Clinic, it can cause serious unwanted effects or fatal overdose in children. Human error CBC News reached out to Loblaws, the company that owns Shoppers Drug Mart. In a written statement, the company said the incident was a case of "human error" that never should have happened. "We have controls in place to minimize risks like this — where the patient was handed the wrong prescription bag — and the associate will review these with employees to avoid a similar situation in the future," the company said. Paquin says she has since heard from the pharmacist, who was very apologetic. She says he acknowledged that steps were missed and standards were dropped, and told her the employee who dispensed the medication has been suspended pending an internal investigation. Asking for accountability Despite his reassurances, Paquin has filed a complaint with the College of Pharmacists of B.C. "The pharmacy needs to take responsibility, be held accountable for what happened," she said. In an email, the college told CBC News it takes these types of errors very seriously. "We have legal requirements in the Health Professions Act bylaws in place to prevent these occurrences, including mandatory standards for prescription preparation to ensure accuracy of the prescription product and consultations for all prescriptions, to make sure clients understand their medication, how to take it properly, and address any questions," the college said. As part of pharmacists' consultation with clients, they are required to confirm the person's identity, name and the strength and purpose of the drug, it added. In 2023-24, the college says it received a total of 990 concerns through its intake process. Of those, 54 became formal complaints and investigations, 16 of which were medication related. Paquin decided to share her ordeal on social media, to warn others to check their prescription before taking it. "It's scary that it happened to us, but I'm also in a way kind of thankful that it happened to us and we caught it because it could have been given to somebody who didn't notice and got hurt," she said.
Yahoo
16 hours ago
- Yahoo
Texas Hospital Discharged Woman with Untreated Ectopic Pregnancy. Then She Started Bleeding Out: ‘Oh My God, I'm Dying'
Kyleigh Thurman filed a complaint against Ascension Seton Williamson Hospital after suffering an ectopic pregnancy. The medical emergency led to a ruptured fallopian tube that caused heavy bleeding A federal investigation has now found that the hospital broke the law by failing to give Thurman proper medical careA federal investigation has found that a Texas hospital broke the law by failing to give a woman proper medical attention following an emergency pregnancy complication. In August 2024, Kyleigh Thurman filed a complaint against Ascension Seton Williamson Hospital over a February 2023 visit when she suffered an ectopic pregnancy. According to the Mayo Clinic, ectopic pregnancy "occurs when a fertilized egg implants and grows outside the main cavity of the uterus." This type of pregnancy cannot proceed normally because "the fertilized egg can't survive,' and it can lead to 'life-threatening bleeding, if left untreated." Court documents claim the hospital discharged Thurman, 36, without treatment, after allegedly giving her a pamphlet about miscarriage. She later returned due to continuous vaginal bleeding, but was 'denied care' again. 'It was not until her OB/GYN pleaded to hospital staff that she be given care that the hospital provided the necessary care,' the filing states. 'This care was too late, and Ms. Thurman's ectopic pregnancy ruptured due to the hospital's delay in treating her.' It was during this third visit to Ascension Seton Williamson Hospital that Thurman was reportedly told her case was now severe and her life was at risk due to the heavy bleeding. The untreated ectopic pregnancy resulted in one of her fallopian tubes rupturing. '[My OB/GYN] came in and she's like, you're either going to have to have a blood transfusion, or you're going to have to have surgery or you're going to bleed out,' Thurman told the Associated Press, through tears. 'That's when I just kind of was like, 'Oh my God, I'm, I'm dying.'' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Thurman underwent emergency surgery to remove one of her fallopian tubes, ultimately jeopardizing her fertility moving forward. A spokesperson for Ascension Seton Williamson Hospital tells PEOPLE that they cannot comment on Thurman's case, but noted that it 'is committed to providing high-quality care to all who seek our services.' Shortly after Thurman's complaint was filed, the Centers for Medicare and Medicaid Services (CMS) launched a federal investigation into her case. According to AP, investigators concluded in a report last month that Ascension Seton Williamson Hospital failed to give her a proper medical screening exam, including an evaluation with an OB-GYN. The hospital also reportedly violated the federal Emergency Medical Treatment and Labor Act (EMTALA), which requires emergency rooms to provide stabilizing treatment to all patients in medical emergencies. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! The report stated, per the outlet, that Thurman was 'at risk for deterioration of her health and wellbeing as a result of an untreated medical condition.' 'We see patients with miscarriages being denied care, bleeding out in parking lots. We see patients with nonviable pregnancies being told to continue those to term,' Molly Duane, an attorney at the Center for Reproductive Rights that represented Thurman, told the outlet. 'This is not, maybe, what some people thought abortion bans would look like, but this is the reality.' Abortion is currently banned in Texas after six weeks, which is before most people know they're pregnant. The law does not allow exceptions for women who were impregnated as a result of rape or incest. Under the legislation, private citizens can also sue doctors or abortion clinic workers who perform or help to set up the procedure. The near-total ban has led to numerous claims of delayed pregnancy-related care — even for care that is legal under state law — due to fear of the extreme penalties for physicians who violate the abortion ban. In 2022, the Biden administration released guidance specifying that hospitals must provide an abortion if needed to treat a patient with an emergency condition. States including Texas challenged that guidance, saying it equated an abortion mandate. On June 3, the CMS announced that it would revoke the Biden-era guidance, explaining in a statement that it would 'work to rectify any perceived legal confusion and instability caused by the former administration's actions.' 'CMS will continue to enforce EMTALA, which protects all individuals who present to a hospital emergency department seeking examination or treatment, including for identified emergency medical conditions that place the health of a pregnant woman or her unborn child in serious jeopardy,' the agency said. However, Thurman told AP that she had hoped the investigation would lead to a more clear message that ectopic pregnancies must be treated by hospitals despite state abortion bans. 'I didn't want anyone else to have to go through this,' Thurman said. 'I put a lot of the responsibility on the state of Texas and policy makers and the legislators that set this chain of events off.' Read the original article on People
Yahoo
17 hours ago
- Yahoo
Alzheimer's blood test can accurately pick up early symptoms
A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. "This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting," he added. "While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed."
